Roche's Gazyva Targets Unmet Need in Rare Kidney Disease with Second FDA Priority Review

FDA grants priority review for Roche's Gazyva in primary membranous nephropathy; stock is flat as traders await H1 results on July 23.

Shares of Roche barely budged on the announcement that the US Food and Drug Administration had granted priority review to Gazyva/Gazyvaro for primary membranous nephropathy (pMN), a rare autoimmune kidney disorder with no currently approved therapy. The stock closed at CHF 323.90 on Tuesday, leaving it down 3.39% on the week and 0.67% over the past month — a muted response that suggests traders have already turned their attention to the company's first-half results due on July 23.

The FDA's decision, confirmed on July 15, means a verdict on the drug's approval for pMN is expected by November 2026. The accelerated review is based on data from the Phase III MAJESTY trial, which compared Gazyva against the current off-label standard, Tacrolimus, over a two-year period. Roche reported that patients receiving Gazyva achieved complete remission at a significantly higher rate — a key endpoint for preserving kidney function in a disease where up to 30% of patients progress to kidney failure within a decade if left untreated.

This marks the second priority review for the drug in just a few months, following a similar designation in May for idiopathic nephrotic syndrome. Already carrying a Breakthrough Therapy tag for pMN, Gazyva is rapidly expanding its footprint beyond its origins in haematology. Roche aims to reduce its dependence on traditional oncology blockbusters, and the nephrology pipeline is a pillar of that strategy. Separately, the European Medicines Agency is assessing Gazyva for lupus nephritis.

Roche’s Chief Medical Officer, Levi Garraway, described the mechanism as targeting tissue-resident B cells, which are thought to drive the autoimmune attack on the kidneys. The MAJESTY results were presented at the European Renal Association congress in June and simultaneously published in the New England Journal of Medicine. Roche has now begun submitting the data to other regulators, including the EMA.

For now, Gazyva remains a pipeline asset without revenue contribution. Whether the regulatory momentum brightens Roche's narrative when it reports half-year figures next week remains to be seen. Analysts will be watching not only for pipeline progress but also for how the company's operating growth holds up against a strong Swiss franc, which has weighed on recent earnings.